Hua Medicine Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 424

Employees

  • Stock Symbol
  • 02552

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.26
  • (As of Friday Closing)

Hua Medicine General Information

Description

Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Number 275 Ai Di Sheng Road
  • Zhangjiang Hi-Tech Park
  • Pudong, Shanghai 201203
  • China
+86
Primary Industry
Drug Discovery
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • Number 275 Ai Di Sheng Road
  • Zhangjiang Hi-Tech Park
  • Pudong, Shanghai 201203
  • China
+86

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hua Medicine Stock Performance

As of 20-Nov-2026, Hua Medicine’s stock price is $0.26. Its current market cap is $257M with 999M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.26 $0.26 $0.25 - $0.50 $257M 999M 1.13M -$0.02

Hua Medicine Financials Summary

As of 30-Jun-2026, Hua Medicine has a trailing 12-month revenue of $93.5M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 157,295 282,407 34,402 154,951
Revenue 93,522 68,546 35,662 10,828
EBITDA (11,338) 157,896 (30,714) (25,951)
Net Income (15,404) 153,846 (34,861) (29,857)
Total Assets 222,990 210,061 209,215 243,401
Total Debt 52,141 43,116 41,120 23,665
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Hua Medicine Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hua Medicine‘s full profile, request access.

Request a free trial

Hua Medicine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-clas
Drug Discovery
Pudong, China
424 As of 2026

Stockholm, Sweden
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Hua Medicine Competitors (47)

One of Hua Medicine’s 47 competitors is Diamyd Medical, a Corporation company based in Stockholm, Sweden.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Diamyd Medical Corporation Stockholm, Sweden
Agios Pharmaceuticals Formerly VC-backed Cambridge, MA
Voyager Therapeutics Formerly VC-backed Lexington, MA
Astellas Pharma Corporation Tokyo, Japan
Neuphoria Therapeutics Corporate Backed or Acquired Millis, MA
You’re viewing 5 of 47 competitors. Get the full list »

Hua Medicine Patents

Hua Medicine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024284286-A1 Glucokinase activator for cognitive disorders and neurodegenerative diseases Pending 06-Jun-2023
EP-4725482-A1 Glucokinase activator for cognitive disorders and neurodegenerative diseases Pending 06-Jun-2023
US-20260248766-A1 Glucokinase activator for cognitive disorders and neurodegenerative diseases Pending 06-Jun-2023
WO-2024251159-A1 Glucokinase activator for cognitive disorders and neurodegenerative diseases Inactive 06-Jun-2023
JP-2026519840-A Glucokinase activators for cognitive impairment and neurodegenerative diseases Pending 06-Jun-2023 A61K31/4155
To view Hua Medicine’s complete patent history, request access »

Hua Medicine Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hua Medicine Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Hua Medicine‘s full profile, request access.

Request a free trial

Hua Medicine Acquisitions (1)

Hua Medicine’s most recent deal was a Merger/Acquisition with Nanjing Shengderui Pharmaceutical for . The deal was made on 02-Dec-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Nanjing Shengderui Pharmaceutical 02-Dec-2022 Merger/Acquisition Drug Discovery
To view Hua Medicine’s complete acquisitions history, request access »

Hua Medicine ESG

Risk Overview

Risk Rating

Updated April, 30, 2023

34.76 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 16,421

Rank

Percentile

Pharmaceuticals

Industry

of 928

Rank

Percentile

Pharmaceuticals

Subindustry

of 456

Rank

Percentile

To view Hua Medicine’s complete esg history, request access »

Hua Medicine Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Nanjing Shengderui Pharmaceutical Nanjing, China 2018

Hua Medicine FAQs

  • When was Hua Medicine founded?

    Hua Medicine was founded in 2011.

  • Where is Hua Medicine headquartered?

    Hua Medicine is headquartered in Pudong, China.

  • What is the size of Hua Medicine?

    Hua Medicine has 424 total employees.

  • What industry is Hua Medicine in?

    Hua Medicine’s primary industry is Drug Discovery.

  • Is Hua Medicine a private or public company?

    Hua Medicine is a Public company.

  • What is Hua Medicine’s stock symbol?

    The ticker symbol for Hua Medicine is 02552.

  • What is the current stock price of Hua Medicine?

    As of 20-Nov-2026 the stock price of Hua Medicine is $0.26.

  • What is the current market cap of Hua Medicine?

    The current market capitalization of Hua Medicine is $257M.

  • What is Hua Medicine’s current revenue?

    The trailing twelve month revenue for Hua Medicine is $93.5M.

  • Who are Hua Medicine’s competitors?

    Diamyd Medical, Agios Pharmaceuticals, Voyager Therapeutics, Astellas Pharma, and Neuphoria Therapeutics are some of the 47 competitors of Hua Medicine.

  • What is Hua Medicine’s annual earnings per share (EPS)?

    Hua Medicine’s EPS for 12 months was -$0.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process